Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207635 · ClinicalTrials.gov registry record
Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 42
- Enrollment target
NCT01207635 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants.
The verdict
NCT01207635 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.
Interventions
- PROCEDURE Ductal Lavage Fluid Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2002-11 |
| Est. Completion | 2006-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01207635
The ClinicalTrials.gov registry entry for NCT01207635 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ductal Lavage Fluid Collection is the first listed.
NCT01207635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01207635 about?
NCT01207635 is a clinical study titled "Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer". The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assess...
What is the current status of trial NCT01207635?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2002-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT01207635?
The interventions under investigation include: Ductal Lavage Fluid Collection (PROCEDURE).
Who is sponsoring clinical trial NCT01207635?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.